ImmunityBio, Inc.
IBRXHealthcareNASDAQBiotechnology · Last scanned Oct 23, 2026
Scan Results
Daily timeframePart of the healthcare sector, ImmunityBio, Inc. (IBRX) is listed under Biotechnology. With a market capitalization of $8.81B, it sits in mid-cap territory. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Market Cap
$8.81B
Beta
0.03
P/E (TTM)
—
P/E (Fwd)
-51.94
EPS (TTM)
$-0.96
EPS (Fwd)
$-0.16
ROE
—
ROA
-30.5%
Cash
$357.4M
Total Debt
$1.23B
Free CF
-$186.6M
52W Change
247.7%
Annual Financials
Cash vs Debt
Where IBRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IBRX finished 5.65% above its 150-day moving average ($7.97) and 10.35% above its 200-day moving average ($7.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IBRX overbought or oversold?
At the October 20, 2026 close, IBRX's RSI(14) was 46.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $357.4M in cash, though total debt stands at $1.23B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$186.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $240K (2022) to $113.3M (2025), reflecting a 47103% increase over the period.
The relatively low beta of 0.03 suggests IBRX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ImmunityBio, Inc. and its sector.